Alexion Pharmaceuticals

Tweet this page
<
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
>
Registration as it was on 12 Jul 2024
How to read and use this data card.
Download this datacard

Overview

Lobbying Costs

100,000€ - 199,999€

Financial year: Jan 2023 - Dec 2023

Lobbyists (Full time equivalent)

0.5 Fte (1)

Lobbyists with EP accreditation

1

High-level Commission meetings

0

Lobbying Costs over the years

  • Info

    Alexion Pharmaceuticals   (Alexion)

    EU Transparency Register

    611074012464-89 First registered on 18 Dec 2013

    Goals / Remit

    Alexion Pharmaceuticals, Inc. now part of Astra Zeneca, is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with severe and life-threatening diseases that are also ultra-rare. Patients with these devastating diseases often have no effective treatment options, and they and their families suffer with little hope.

    Main EU files targeted

    Alexion monitors and follows policy of relevance for the biopharmaceutical sector. It interacts with the EU institutions and engages in issues relating to healthcare, pharmaceuticals, patient safety, research and innovation, competitiveness and internal market.

    Address

    Head Office
    121 Seaport Boulevard
    Boston MA 02210
    UNITED STATES
    EU Office
    Alexion Pharma GmbHNeuhofstrasse 34
    Baar 6340
    SWITZERLAND

    Website

  • People

    Total lobbyists declared

    1

    Employment timeLobbyists
    50%1

    Lobbyists (Full time equivalent)

    0.5

    Lobbyists with EP accreditation

    All Lobbyists with EP accreditation over time

    1 accreditations were / are live (in bold) for the selected state of 27 Dec 2024

    Name Start date End Date
    Matthias Heck 02 Sep 2024 01 Sep 2025
    Matthias Heck 28 Jun 2023 28 Jun 2024
    Matthias Heck 14 Feb 2020 01 Mar 2021
    Matthias Heck 02 Aug 2018 01 Sep 2019
    Claire ALBANO 17 Oct 2017 08 Jun 2018
    Mr Thibault, Marie Bruno De Lary de Latour 17 Oct 2017 21 Sep 2018
    Matthias Heck 27 Jun 2017 21 Jun 2018
    Claire ALBANO 22 Oct 2016 17 Oct 2017
    Mr Thibault, Marie Bruno De Lary de Latour 22 Oct 2016 17 Oct 2017
    Mr Gregory KALBAUGH 30 Sep 2016 23 Sep 2017
    Mr David Newman 22 Aug 2016 30 Jul 2017
    Matthias Heck 20 Feb 2016 19 Feb 2017
    Ms Heidi Wagner 29 Oct 2015 23 Oct 2016
    Claire ALBANO 29 Oct 2015 22 Oct 2016
    Mr Thibault, Marie Bruno De Lary de Latour 29 Oct 2015 22 Oct 2016
    Ms Grainne Madeline Crowley 29 Oct 2015 23 Oct 2016
    Mr Gregory KALBAUGH 04 Sep 2015 02 Sep 2016
    Ms Grainne Madeline Crowley 20 Nov 2014 29 Oct 2015
    Mr Thibault, Marie Bruno De Lary de Latour 20 Nov 2014 29 Oct 2015
    Mrs Grainne Madeline Crowley 20 Nov 2014 27 Jan 2015
    Ms Heidi Wagner 19 Nov 2014 29 Oct 2015
    Mr André Zöller 19 Nov 2014 29 Jul 2015
    Claire ALBANO 19 Nov 2014 29 Oct 2015

    Complementary Information

    The Government Affairs team covers a broad range of activities that go beyond EU policies. This explains the percentage indicated for EU related activities.

    Person in charge of EU relations

    Data not provided by Register Secretariat due to GDPR

    Person with legal responsibility

    Data not provided by Register Secretariat due to GDPR

  • Categories

    Category

    Companies & groups

  • Networking

    Affiliation

    Alexion is member of the following organisations in Brussels:
    - EUCOPE - European Confederation of Pharmaceutical Entrepreneurs
    - EuropaBio
    - EURORDIS Roundtable of Companies (ERTC) - European Organisation for Rare Diseases
    - EFPIA (via Astra Zeneca)
    - Friends of Europe
    - Avicenna Alliance

    Member organisations

    None declared

  • Financial Data

    Interests represented

    Promotes their own interests or the collective interests of their members

    Closed financial year

    Jan 2023 - Dec 2023

    Lobbying costs for closed financial year

    100,000€ - 199,999€

    Major contributions in closed year

    None declared

    Intermediaries for closed year

    NameAmount
    concilius 200,000€ - 299,999€
    fipra 50,000€ - 99,999€

    Intermediaries for current year

    Name
    concilius

    Closed year Costs

    100,000€ - 199,999€

    Other financial info

    None declared

  • EU Structures

    Groups (European Commission)

    None declared

    Groups (European Parliament)

    N/A

    Communication activities

    - Revision of EU Orphan Drug Legislation
    - European Commission Pharmaceutical Strategy
    - Potential amendments of Directive 2001/83 and Regulation 724/2006

    Other activities

    None declared

  • Meetings

    Meetings

    None declared

Download this datacard